(Q50631723)

16 March 2018

title

Economic evaluation of pertussis prevention by whole-cell and acellular vaccine in Germany. (English)

1 reference

16 March 2018

author name string

G Tormans

1

1 reference

16 March 2018

E Van Doorslaer

2

1 reference

16 March 2018

P van Damme

3

1 reference

16 March 2018

R Clara

4

1 reference

16 March 2018

H J Schmitt

5

1 reference

16 March 2018

publication date

1 May 1998

1 reference

16 March 2018

European Journal of Pediatrics

published in

1 reference

16 March 2018

volume

157

1 reference

16 March 2018

issue

5

1 reference

16 March 2018

page(s)

395-401

1 reference

16 March 2018

https://scigraph.springernature.com/pub.10.1007/s004310050837

exact match

0 references

cites work

Adverse reactions and antibody responses to acellular pertussis vaccine

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Comparison of acellular (B type) and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines as the first booster immunization in 15- to 24-month-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Pertussis Vaccine — An Analysis of Benefits, Risks and Costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Neurological complications of pertussis inoculation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

The acellular pertussis vaccine trials: an interpretation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Pertussis in Sweden after the cessation of general immunization in 1979.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Efficacy of acellular pertussis vaccine in early childhood after household exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

A Controlled Trial of Two Acellular Vaccines and One Whole-Cell Vaccine against Pertussis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24- and 2- to 4-month-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS004310050837

Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs

21 January 2018

1 reference

12 December 2020

Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany

1 reference

12 December 2020

The benefit of immunization against whooping cough

1 reference

12 December 2020

Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.

1 reference

12 December 2020

Pertussis and pertussis vaccine: further analysis of benefits, risks and costs.

1 reference

12 December 2020

Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children

1 reference

12 December 2020

Type-specific efficacy of acellular pertussis vaccine

1 reference

12 December 2020

1 reference

12 December 2020

Efficacy and safety of acellular pertussis vaccine in Aichi Prefecture, Japan

1 reference

12 December 2020

Seroepidemiology of pertussis in the Japanese population

1 reference

12 December 2020

Epidemiology of pertussis in a developed country with low vaccination coverage: the Italian experience

1 reference

12 December 2020

Two trials of an acellular DTP vaccine in comparison with a whole-cell DTP vaccine in infants: evaluation of two PT doses and two vaccination schedules

1 reference

12 December 2020

Longitudinal study of adverse reactions following diphtheria-tetanus-pertussis vaccine in infancy.

1 reference

12 December 2020

How safe are pertussis and rubella vaccines? A commentary on the Institute of Medicine Report

1 reference

12 December 2020

Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children

1 reference

12 December 2020

The epidemiological situation of pertussis in the Federal Republic of Germany

1 reference

12 December 2020

Acellular pertussis vaccination of 2-month-old infants in the United States

1 reference

12 December 2020

The epidemiology of whooping cough

1 reference

12 December 2020

Diphtheria-pertussis-tetanus vaccine: reactogenicity of commercial products

1 reference

12 December 2020

Immunogenicity and reactogenicity of Takeda acellular pertussis-component diphtheria-tetanus-pertussis vaccine in 2- and 3-month-old children in Japan

1 reference

12 December 2020

Identifiers

DOI

10.1007/S004310050837

1 reference

16 March 2018

PubMed ID

9625337

1 reference

16 March 2018